Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 2994-3002

  Morrill, J C ^a,c   Peters, C J ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Applied Research Division   (United States)

Author keywords

Neurovirulence; Rift Valley fever; Vaccine

Indexed keywords

MUTAGEN ATTENUATED RIFT VALLEY FEVER VACCINE; MUTAGENIC AGENT; UNCLASSIFIED DRUG; VIRUS VACCINE; YELLOW FEVER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG USE; HISTOPATHOLOGY; IMMUNOPATHOLOGY; LABORATORY TEST; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; RHESUS MONKEY; RIFT VALLEY FEVER BUNYAVIRUS; VIROLOGY; VIRUS VIRULENCE;

EID: 0038512604     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00131-2     Document Type: Article

References (23)

1. Meegan J.M., Hoogstral H., Moussa M.I. An epizootic of Rift Valley fever virus in Egypt in 1977. Vet. Rec. 105:1979;124-125.
2. Centers for Disease Control and Prevention. Outbreak of Rift Valley fever - Yemen, August-October 2000. Morbidity Mortality Wkly. Rep. 2000;49(47):1065-6.
3. Randall R., Binn L.N., Harrison V.R. Immunization against Rift Valley fever virus: studies on the immunogenicity of lyophilized, formalin-inactivated vaccine. J. Immunol. 93:1964;293-299.
4. Caplen H., Peters C.J., Bishop D.H.L. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66:1985;2271-2277.
5. Morrill J.C., Jennings G.B., Caplen H., Turell M.J., Johnson A.J., Peters C.J. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am. J. Vet. Res. 48:1987;1042-1047.
6. Morrill J.C., Carpenter L., Dalrymple J., Peters C.J. Further evaluation of ZH-548 strain MP12 as a live attenuated Rift Valley fever vaccine for sheep. Vaccine. 9:1991;35-41.
7. Hubbard K.A., Baskerville A., Stephenson J.R. Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever. Am. J. Vet. Res. 52:1991;50-55.
8. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res. 58:1997;1104-1109.
9. Morrill J.C., Mebus C.A., Peters C.J. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am. J. Vet. Res. 58:1997;1110-1114.
10. Peters C.J., Jones D., Trotter R.et al. Experimental Rift Valley fever in rhesus macaques. Arch Virol. 99:1988;31-44.
11. Morrill J.C., Jennings G.B., Johnson A.J., Cosgriff T.M., Gibbs P.H., Peters C.J. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch Virol. 110:1990;195-212.
12. Cosgriff T.M., Morrill J.C., Jennings G.B.et al. The hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys. Rev. Infect. Dis. II(Suppl. 4):1989;S807-814.
13. Centers for Disease Control and National Institute of Health. Biosafety in microbiological and biomedical laboratories. 3rd ed. US Department of Health and Human Services: Public Health Service; 1993. p. 24-32.
14. Angsubhakorn S., Moe J.B., Latendresse J.R.et al. The neurovirulence of flaviviruses in crab-eating monkeys (Macaca fascicularis). SE Asian J. Trop. Med. Pub. Hlth. 17(4):1986;604-612.
15. Meegan J.M., Yedloutschnig R.J., Peleg B.A.et al. Enzyme-linked immunosorbent assay for detection of antibodies to Rift Valley fever virus in ovine and bovine sera. Am. J. Vet. Res. 48:1987;1138-1141.
16. Ksiazek T.G., Jouan A., Meegan J.M.et al. Rift Valley fever among domestic animals in the recent West African outbreak. Res. Virol. 140:1989;67-77.
17. Arborio M., Hall W.C. Diagnosis of a human case of Rift Valley fever by immunoperoxidase demonstration of antigen in fixed liver tissue. Res. Virol. 40:1989;165-168.
18. Morrill J.C., Jennings G.B., Cosgriff T.M., Gibbs P.H., Peters C.J. Prevention of Rift Valley fever in rhesus monkeys with interferon-α Rev. Infect. Dis. II(Suppl. 4):1989;S815-825.
19. Turell M.J., Rossi C.A. Potential for mosquito transmission of attenuated strains of Rift Valley fever virus. Am. J. Trop. Med. Hyg. 44:1991;278-282.
20. Saluzzo J.F., Smith J.F. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine. 8:1990;369-375.
21. Nathanson N., Davis M., Thind I.S., Price W.H. Histological studies of the neurovirulence of group B arboviruses. II. Selection of indicator centers. Am. J. Epidemiol. 84:1966;524-540.
22. Jennings A.D., Gibson C.A., Miller B.R.et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169:1994;512-518.
23. Peters CJ, Linthicum KJ. Rift Valley fever. In: Beran G, editor. CRC handbook of zoonoses. Section B: viral. 2nd ed. Boca Raton: CRC Press; 1994. p. 25-138.